Category - Markets

RBC Capital Markets initiated coverage of TSO3 (TSX:TOS) with an “outperform, speculative risk” rating and $4.25 (Canadian) price target. The stock closed at $3.09 on May 2. TSO3 recently commercialized a highly...

Leerink downgraded Intra-Cellular Therapies (NASDAQ:ITCI) to “market perform” from “outperform” and slashed its price target to $10 from $29, following a corporate update highlighting an unusual preclinical safety...

Roth Capital Partners raised its price target for Conatus Pharmaceuticals (NASDAQ:CNAT) to $12 from $4, reflecting a revised valuation. The stock closed at $7.58 on April 21. Analyst Sa’ar Yaniv writes that the revision...

BTIG initiated coverage of Cascadian Therapeutics (NASDAQ:CASC) with a “buy” rating and $13 price target. The stock closed at $3.92 On April 20. Cascadian is focused on the development of Tucatinib, an oral, highly...

Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and $9 price target. The stock closed at $4.90 on April 19. “We expect a number of events over the coming 12 months to drive investor...

Roth Capital Partners initiated coverage of Poxel SA (NXT:PA) with a “buy” rating and price target of €11. The stock was recently quoted at €5.14. Poxel’s Imeglimin has demonstrated promising efficacy for the treatment...

Roth Capital Markets launched coverage on Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and $2 price target. The stock closed at 77 cents on April 19. “Following positive results from a randomized Phase 2 study...

CIBC World Markets initiated coverage of Theratechnologies (TSX:TH) with an “outperform” rating and $10 price target. The stock closed at $5.95 on April 19. Theratechnologies has a focused strategy and business plan to...

Leerink upgraded Immunogen (NASDAQ:IMGN) to “outperform” from “market perform” and raised its price target to $8 from $2 based on a “higher level of conviction” on lead asset, mirvetuximab soravtansine, providing an...

BTIG initiated coverage of Quotient (NASDAQ:QTNT) with a “buy” rating and $22 price target. The stock closed at $6.26 on April 17. British-based Quotient develops and commercializes tests for blood grouping and...